Jon Hu

@Jonyuhu

Co-founder and CEO @pepper_bio | Biotech nerd
@HarvardHBS MBA | @NorthwesternU Undergrad
Former @BainAlerts, @TakedaPharma (Shire Pharma)

Joined September 2012

50 Following 24 Followers 10 Posts

Latest posts 5

Jon Hu @Jonyuhu Jan 12, 2024

Shared my thoughts on 2024's pharma trends with @PharmaVoice's @MeaganParrish. Despite the challenges ahead there are big opportunities too. More on how March-In rights might impact biotech, and other trends from industry leaders here: bit.ly/3ScB21H

www.pharmavoice.com Pharma execs sound off on trends and policies they’re tracking in 2024 From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

Pepper Bio @pepper_bio Jan 12, 2024

At #JPM2024, our CEO @jonyuhu shared with @PharmaVoice's @MeaganParrish his perspective on what policies will shape biotech in 2024. '"It's not the first time we've heard of march-in rights, but [they] are more mainstream now,' he says. More here: bit.ly/3ScB21H
View quoted post on X

Jon Hu @Jonyuhu Jan 10, 2024

@PepperBio is featured in @TechCrunch’s Pitch Deck Teardown! @Haje's insights on our $6.5M seed pitch stress the value of personal connections in biotech – a reminder to tailor messages effectively when merging science and storytelling bit.ly/3tGM31X

Jon Hu @Jonyuhu Jan 5, 2024

Join us in giving a warm welcome to Dr. Martin Alexander Gershon, @endeavorfunds, who is starting his role as our senior strategic advisor. Read about his role with @pepper_bio here: bit.ly/48lFH7j
#transomics #drugdiscovery

Jon Hu @Jonyuhu Dec 29, 2023

How are startups already using AI to transform the way we approach drug discovery? More on this in @WSJ via my conversation with @BrianPGormley and @SamanthaDStrass.
wsj.com/articles/start…

Jon Hu @Jonyuhu Dec 18, 2023

My op-ed in @statnews explores how patient advocacy groups influence FDA approvals for drugs that don’t have robust clinical data proving impact. Here’s why that's a problem & how I think we can positively redirect patient advocacy for better outcomes: bit.ly/3GPjxhE

www.statnews.com Alzheimer’s drug approvals show we need a reevaluation of patient advocacy The current state of patient advocacy needs reform so that the best, safest drugs come to market, writes Jon Hu of Pepper Bio.